证券代码：688506 证券简称：百利天恒 公告编号：2025-036 四川百利天恒药业股份有限公司 关于参加 2024 年度科创板创新药行业集体业绩说明会暨 召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 30 日(星期三)至 5 月 7 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过四川百利天恒药业股份 有限公司（以下简称"公司"）邮箱 ir@baili-pharm.com 进行提问，公司将在说 明会上对投资者普遍关注的问题进行回答。 （一） 会议召开时间：2025 年 5 月 8 日（星期四）15:00-17:00 公司已于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 公司 2024 年年度报告，并于 2025 年 4 月 30 日披露 2025 年第一季度报告，为便 于广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度的经营成 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥67,439,982.29, a decrease of 98.77% compared to ¥5,462,123,134.28 in the same period last year[4] - The net profit attributable to shareholders was -¥531,435,850.51, representing a decline of 110.62% from ¥5,005,155,365.45 year-on-year[4] - Basic and diluted earnings per share were both -¥1.33, down 110.66% from ¥12.48 in the previous year[4] - The company reported a significant decrease in net profit due to a sharp decline in operating revenue and an increase in R&D expenses[7] - The net loss for Q1 2025 was CNY 531,435,850.51, a stark contrast to a net profit of CNY 5,005,155,365.45 in Q1 2024[19] - The company reported a total comprehensive loss of CNY -530,297,772.33 in Q1 2025, compared to a comprehensive income of CNY 5,003,708,460.37 in Q1 2024[20] Research and Development - Research and development expenses totaled ¥494,913,002.18, an increase of 98.95% compared to ¥248,767,838.91 in the previous year[5] - The ratio of R&D expenses to operating revenue surged to 733.86%, up by 729.31 percentage points from 4.55% in the previous year[5] - The company aims to accelerate the R&D progress of its product pipeline to maintain its competitive advantage and expedite product launches[7] - The company is focusing on expanding its R&D efforts, as indicated by the substantial increase in R&D expenses[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥489,838,426.73, a decline of 109.11% from ¥5,378,961,733.25 in the same period last year[4] - Total cash inflow from operating activities in Q1 2025 was 183,689,270.20, down from 5,829,179,801.63 in Q1 2024[22] - Cash outflow from operating activities increased to 673,527,696.93 in Q1 2025, compared to 450,218,068.38 in Q1 2024[23] - Cash flow from investing activities showed a net inflow of 209,854,280.88 in Q1 2025, contrasting with a net outflow of -9,184,007.40 in Q1 2024[23] - Cash inflow from financing activities rose to 1,010,000,000.00 in Q1 2025, compared to 100,000,000.00 in Q1 2024[23] - The net cash flow from financing activities was 738,974,554.43 in Q1 2025, up from 54,781,142.67 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was 3,661,101,912.06, compared to 5,811,813,000.70 in Q1 2024[24] - The company received 10,042,314.81 in tax refunds in Q1 2025, an increase from 3,423,343.57 in Q1 2024[22] - The company paid 201,852,112.05 in employee compensation in Q1 2025, compared to 113,533,587.71 in Q1 2024[23] - The cash outflow for other operating activities was 386,816,933.38 in Q1 2025, compared to 279,735,605.89 in Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,439,191,804.86, an increase of 4.23% from ¥7,137,357,660.07 at the end of the previous year[5] - Total liabilities increased to CNY 4,067,763,407.83 in Q1 2025 from CNY 3,251,432,880.03 in Q1 2024, marking an increase of approximately 25%[15] - The company's total equity decreased to CNY 3,371,428,397.03 in Q1 2025 from CNY 3,885,924,780.04 in Q1 2024, reflecting a decline of about 13%[15] - Shareholders' equity attributable to shareholders decreased by 13.24% to ¥3,371,428,397.03 from ¥3,885,924,780.04 at the end of the previous year[5] - The total current assets as of March 31, 2025, amounted to ¥6,568,169,083.49, an increase from ¥6,307,204,588.11 as of December 31, 2024, representing a growth of approximately 4.14%[12] - Cash and cash equivalents increased to ¥3,667,937,163.82 from ¥3,220,120,969.20, reflecting a rise of about 13.9%[12] - Inventory levels rose to ¥192,941,670.97 from ¥162,191,590.25, indicating an increase of approximately 18.98%[13] - The company's long-term assets totaled ¥871,022,721.37, up from ¥830,153,071.96, which is an increase of about 4.2%[13] - Accounts receivable decreased to ¥80,167,866.70 from ¥106,715,664.97, showing a decline of approximately 25%[13] - The company reported a significant increase in prepayments, which rose to ¥97,392,571.25 from ¥81,590,484.92, reflecting a growth of about 19.4%[13] Shareholder Information - There were no changes in the top 10 shareholders or their shareholding status due to margin trading activities[11] - The company has not identified any related party transactions among its major shareholders[11] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12]

Group 1 - The company's operating revenue for the first quarter of 2025 is 67.44 million, representing a year-on-year decline of 98.77% [1] - The company reported a net loss of 531 million, compared to a net profit of 5.005 billion in the same period last year [1]

Group 1 - The State Council Information Office will hold a press conference on April 28 to discuss policies related to stabilizing employment and the economy, promoting high-quality development [1] - The National Development and Reform Commission, Ministry of Human Resources and Social Security, Ministry of Commerce, and the People's Bank of China will present relevant measures and answer questions [1] Group 2 - The China Council for the Promotion of International Trade will hold a press conference on April 28 to release the global trade friction index for February 2025 and other trade-related data [3] - The press conference will also cover the latest preparations for the third Chain Expo and new policies to support foreign trade [3] Group 3 - The China Meteorological Administration will hold a press conference on April 28 to discuss the national weather and climate characteristics for April, as well as predictions for May [4] Group 4 - The first "Beijing Xiangshan Forum" will take place from April 28 to 30, focusing on global security challenges and opportunities, with participation from over 200 defense officials and experts from more than 30 countries [5] Group 5 - On April 28, a total of 17 companies will have their restricted shares released, amounting to 1.727 billion shares with a total market value of 24.677 billion yuan [6] - Companies with the highest share unlock volumes include China Resources Materials, Chengda Bio, and Wangbian Electric [6] Group 6 - 19 companies announced stock repurchase progress on April 28, with 18 companies disclosing new repurchase plans [7] - The highest repurchase amounts were reported by Tianyuan Environmental Protection, Jinli Permanent Magnet, and Zhenhua Heavy Industry [7] Group 7 - A total of 176 billion yuan in 7-day reverse repos will mature today, with an operation rate of 1.5% [8]

证券代码：688506 证券简称：百利天恒 公告编号：2025-035 四川百利天恒药业股份有限公司 自愿披露关于 BL-B01D1（EGFR×HER3 双抗 ADC）联合用 药治疗复发或转移性宫颈癌和晚期或复发性子宫内膜癌获得 受理号：CXSL2500114、CXSL2500119 通知书编号：2025LP01174、2025LP01175 申请事项：境内生产药品注册临床试验 申请人：成都百利多特生物药业有限责任公司；四川百利药业有限责任公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，注射用 BL-B01D1 临床试验符合药品注册的有关要求，同意本品开展联合帕博利珠单抗 双药不联合或联合贝伐珠单抗和/或化疗治疗复发或转移性宫颈癌、联合帕博利珠 单抗双药不联合或联合化疗治疗晚期或复发性子宫内膜癌的临床试验。 二、药品的其他情况 2 个 II 期药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局(NMPA) ...

中信证券股份有限公司 关于四川百利天恒药业股份有限公司 （四）现场检查时间 2024 年度持续督导工作现场检查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为四川百 利天恒药业股份有限公司（以下简称"百利天恒""公司"或"上市公司"）2025 年度向特定对象发行 A 股股票的保荐人，于 2025 年 3 月 27 日与公司签订保荐 协议，自保荐协议生效之日起，承接原保荐人国投证券股份有限公司尚未完成的 首次公开发行股票并在科创板上市的持续督导工作。根据《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》等有关法律、法规的规定，中信证券 股份有限公司对 2024 年 1 月 1 日至 2024 年 12 月 31 日（以下简称"本持续督导 期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 杨沁、陈溦 （三）现场检查人员 杨沁、陈溦、周增骏、冯暄 2025 年 3 月 17 日至 2025 年 4 月 23 日 （五）现场检查内容 现场检查人员对本持续督导期内上市公司的公司治理和内 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed A Fund, which has shown significant returns in recent months and has a strong portfolio in the healthcare sector [1][3]. - As of April 24, 2025, the fund's latest net value is 1.5450 yuan, reflecting a growth of 1.25% [1]. - The fund has achieved a return of 18.21% over the past month, ranking 2 out of 8 in its category, and a return of 30.60% over the past three months, ranking 1 out of 8 [1]. - Year-to-date, the fund has returned 28.32%, also ranking 1 out of 8 in its category [1]. Group 2 - The top ten stock holdings of the fund account for a total of 64.17%, with significant positions in companies such as Heng Rui Pharmaceutical (10.23%), Kelun Pharmaceutical (9.09%), and Bai Li Tianheng (8.94%) [1]. - The fund was established on June 18, 2015, and as of March 31, 2025, it has a total asset size of 4.408 billion yuan [1]. - The fund manager, Zhang Wei, has a strong background in biomedical studies and has held various positions in the pharmaceutical research field prior to managing this fund [2].

汇添富健康生活一年持有A业绩表现较为突出。 2025年以来的震荡市场中，沪深300指数下跌3.76%，汇添富健康生活一年持有A仍保持36.03%的正收益，跑赢 业绩比较基准超过30个百分点，同类排名34/4575。 重仓股科伦博泰生物、百利天恒年内股价涨幅超四成 汇添富健康生活一年持有基金经理为张韡。公开资料显示，张韡曾任东方证券医药助理研究员，汇添富基金医 药研究员、高级医药研究员及医药行业研究组组长。 截至2025年4月23日数据（下同），该基金近一年收益率达29.23%，成立以来回报率达到16.67%，大幅跑赢业 绩比较基准及同类平均。 基金经理张韡在行业分化中抓住结构性机会，成为近年来健康主题基金的领跑者。2025年以来，基金净值累计 上涨36.03%，同类排名34/4575。 业绩领跑：年内回报达36.03% 汇添富健康生活一年持有A成立于2021年3月，基金采用自下而上的投资方法，以深入的基本面分析为立足点， 精选健康生活主题中的优质上市公司，在科学严格管理风险的前提下，谋求基金资产的中长期稳健增值。 基金业绩比较基准为中证医药卫生指数收益率*50%+中证消费服务领先指数收益率*20%+中债综合指 ...

上市后，百利天恒股价一路上行。截至4月23日收盘，百利天恒股价报收于283.50元，市值站稳千亿元 大关。 值得一提的是，券商看好百利天恒股价仍有上涨空间。4月3日，太平洋证券研究员周豫、霍亮、戎晓婕 发布了对百利天恒的研报《重点关注BL-B01D1海外数据读出和3期临床进展》，该研报对百利天恒给 出"买入"评级。 记者注意到，今年内，百利天恒核心管线BL-B01D1有望在国内申报上市，并有望于今年上半年启动首 个海外III期临床。据开源证券预计，BL-B01D1有望成为肿瘤广谱治疗方案，今年后或陆续获批多个适 应症。 百利天恒股价屡创新高，券商看好后市增长空间 4月22日，百利天恒股价创历史新高。截至当日收盘，百利天恒上涨11.41%，报收于291.51元，最高价 创近一年新高，换手率1.41%，成交量129.89万股，成交额3.62亿元。 自2023年1月6日以24.7元/股的发行价登陆科创板以来，百利天恒股价堪称"一路上行"。早在去年12月， 百利天恒股价摸高至246.3元/股，创下发行以来最高值。如今，在市值突破千亿大关的同时，公司也成 为中国医药科创板板块的首个10倍股。截至4月22日收盘，该股股价 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）近日收到国家药品监督管理局(NMPA)正式批准签 发的《药物临床试验批准通知书》，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）联合 用药的药物临床试验获得批准。现将相关情况公告如下： 一、《药物临床试验批准通知书》基本情况 申请事项：境内生产药品注册临床试验 申请人：成都百利多特生物药业有限责任公司；四川百利药业有限责任公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，注射用BL-M11D1临床试验申请符合 药品注册的有关要求，同意本品开展联合阿糖胞苷+柔红霉素或维奈克拉+阿扎胞苷治疗新诊断的急性 髓系白血病的临床试验。 二、药品的其他情况 BL-M11D1是与BL-B01D1出自同一技术平台、与BL-B01D1共享同一"连接子+毒素"平台的靶向CD33的 ADC药物。截至目前，除本次新获得批准的临床试验外，BL-M11D1正在国内进行Ib期临 ...